Strain Data Sheet

RBRC00357

Strain Information

Image
BRC No.RBRC00357
TypeTargeted MutationCartagena
SpeciesMus musculus
Strain nameC.Cg-Tnc<tm1Sia> Foxn1<nu>/Rbrc
Former Common nameBALB/cA-Tnc<tm1Sia>-nude; BALB/cA-TgH(Tnc)-Foxn1nu
H-2 Haplotype
ES Cell line
Background strainBALB/cA
Appearance
Strain development1998年から開発に着手。開発者、遺伝子基盤研究部・日下部守昭先生。
Strain description細胞外基質テネイシンの腫瘍増殖、腫瘍転移における役割を解析する為に開発を開始した系統。テネシイン機能解析のためのテネシイン欠損マウス系統BALB/cA-Tnc<tm1>に、他系統のマウス腫瘍およびヒト腫瘍が移植可能なnude遺伝子をさらに導入したダブルミュータント。アルビノ。腫瘍増殖、腫瘍転移、血管新生、組織間相互作用、ヒト腫瘍移植など。
Colony maintenancenu/+ x nu/+ または n/n x n/+の交配により維持する。Tncはホモ欠損で固定する。Nude遺伝子の判定のみ行う形にして兄妹交配にて維持する。離乳前後の仔マウスには補助飼料を加える。繁殖効率：A
References
Murine tenascin: cDNA cloning, structure and temporal expression of isoforms.
Y Saga, T Tsukamoto, N Jing, M Kusakabe, T Sakakura
Gene, 104, 177-185 (1991). 1717349

Mice develop normally without tenascin.
Y Saga, T Yagi, Y Ikawa, T Sakakura, S Aizawa
Genes Dev., 6, 1821-1831 (1992). 1383086

Tenascin knockout mice: barrels, boundary molecules, and glial scars.
D A Steindler, D Settles, H P Erickson, E D Laywell, A Yoshiki, A Faissner, M Kusakabe
J. Neurosci., 15, 1971-1983 (1995). 7534342

Abnormal behavior and neurotransmissions of tenascin gene knockout mouse.
F Fukamauchi, N Mataga, Y J Wang, S Sato, A Youshiki, M Kusakabe
Biochem. Biophys. Res. Commun., 221, 151-156 (1996). 8660327

炎症, 15(5), 377-381 (1996).

乳癌基礎研究, 5, 41-45 (1996).

Tyrosine hydroxylase activity and its mRNA level in dopaminergic neurons of tenascin gene knockout mouse.
F Fukamauchi, N Mataga, Y J Wang, S Sato, A Yoshiki, M Kusakabe
Biochem. Biophys. Res. Commun., 231, 356-359 (1997). 9070278

Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture.
N Nakao, N Hiraiwa, A Yoshiki, F Ike, M Kusakabe
Am. J. Pathol., 152, 1237-1245 (1998). 9588892

Effect of tenascin-C deficiency on chemically induced dermatitis in the mouse.
Y Koyama, M Kusubata, A Yoshiki, N Hiraiwa, T Ohashi, S Irie, M Kusakabe
J. Invest. Dermatol., 111, 930-935 (1998). 9856798

22nd Congress of the International Association for Breast Cancer Research Athens, Greece 25-28 September, pp 197-201 (1998). 9863494
more 5 references
Corneal wound healing in tenascin knockout mouse.
A Matsuda, A Yoshiki, Y Tagawa, H Matsuda, M Kusakabe
Invest. Ophthalmol. Visual. Sci., 40, 1071-1080 (1999). 10235540

乳癌基礎研究, 8, 26-31 (1999).

Loss of cortical and thalamic neuronal tenascin-C expression in a transgenic mouse expressing exon 1 of the human Huntington disease gene.
M Kusakabe, L Mangiarini, E D Laywell, G P Bates, A Yoshiki, N Hiraiwa, J Inoue, D A Steindler
J. Comp. Neurol., 430, 485-500 (2001). 11169482

Tenascin-C expression and splice variant in habu snake venom-induced glomerulonephritis.
Kenji Matsumoto, Noriko Hiraiwa, Atsushi Yoshiki, Masatake Ohnishi, Moriaki Kusakabe
Exp. Mol. Pathol., 72, 186-195 (2002). 12009782

PDGF receptor-alpha deficiency in glomerular mesangial cells of tenascin-C knockout mice.
Kenji Matsumoto, Noriko Hiraiwa, Atsushi Yoshiki, Masatake Ohnishi, Moriaki Kusakabe
Biochem. Biophys. Res. Commun., 290, 1220-1227 (2002). 11811993

Health Report

Examination Date / Room / Rack

Gene

Gene SymbolGene NameChr.Allele SymbolAllele NameCommon NamesPromoterDiseases Related to This Gene
Foxn1
MGI:102949		forkhead box N111Foxn1<nu>
MGI:1856108		nude
  • T-cell immunodeficiency, congenital alopecia, and nail dystrophy(DisGeNET, MedGEN)

  • T-cell lymphopenia, infantile, with or without nail dystrophy, autosomal dominant(MedGEN)
    • Tnc
    MGI:101922    		tenascin C4Tnc<tm1Sia>
    MGI:2148540    		targeted mutation 1, Shinichi Aizawa
  • autosomal dominant nonsyndromic hearing loss 56(MedGEN)
    • lacZ beta-galactosidase (E. coli)4
    neo neomycin resistance gene (E. coli)4 mouse phosphoglycerate kinase promoter (PGK promoter)

    Phenotype

    Phenotype annotation from literatures by Mammalian phenotype ontology
  • abnormal CNS synaptic transmission (MP:0002206)

  • abnormal Peyer's patch germinal center morphology (MP:0002391)

  • abnormal Peyer's patch morphology (MP:0000696)

  • abnormal T cell activation (MP:0001828)

  • abnormal T cell physiology (MP:0002444)
    • more 100 phenotypes
  • abnormal circadian behavior (MP:0020467)

  • abnormal circulating cytokine level (MP:0010210)

  • abnormal circulating gonadotropin level (MP:0003361)

  • abnormal coat/ hair morphology (MP:0000367)

  • abnormal compact bone morphology (MP:0003797)

  • abnormal corneocyte morphology (MP:0030605)

  • abnormal cutaneous collagen fibril morphology (MP:0008438)

  • abnormal embryonic tissue morphology (MP:0002085)

  • abnormal epidermal layer morphology (MP:0001216)

  • abnormal epidermis stratum basale morphology (MP:0001231)

  • abnormal epidermis stratum corneum morphology (MP:0001240)

  • abnormal epidermis stratum granulosum morphology (MP:0001239)

  • abnormal estrous cycle (MP:0001927)

  • abnormal hair cortex keratinization (MP:0009801)

  • abnormal hair cortex morphology (MP:0003811)

  • abnormal hair cuticle (MP:0003810)

  • abnormal hair follicle inner root sheath morphology (MP:0010685)

  • abnormal hair follicle morphology (MP:0000377)

  • abnormal hair shaft morphology (MP:0003809)

  • abnormal liver morphology (MP:0000598)

  • abnormal lymph node T cell domain morphology (MP:0002347)

  • abnormal lymph node morphology (MP:0002339)

  • abnormal muscle morphology (MP:0002108)

  • abnormal nail matrix morphology (MP:0012405)

  • abnormal nail morphology (MP:0000579)

  • abnormal nail plate morphology (MP:0012403)

  • abnormal response/metabolism to endogenous compounds (MP:0003638)

  • abnormal serotonin level (MP:0005322)

  • abnormal spleen morphology (MP:0000689)

  • abnormal spleen physiology (MP:0008737)

  • abnormal splenic cell ratio (MP:0008826)

  • abnormal thymus development (MP:0000704)

  • abnormal thymus epithelium morphology (MP:0009544)

  • abnormal thymus morphology (MP:0000703)

  • abnormal trabecular bone morphology (MP:0000130)

  • abnormal venule morphology (MP:0004125)

  • absent B cells (MP:0008071)

  • absent Peyer's patches (MP:0002831)

  • absent lymph nodes (MP:0008024)

  • absent spleen (MP:0000690)

  • absent vibrissae (MP:0001284)

  • ascites (MP:0005324)

  • asthenozoospermia (MP:0002675)

  • athymia (MP:0000705)

  • blepharitis (MP:0005251)

  • chromosomal instability (MP:0008866)

  • coiled sperm flagellum (MP:0009238)

  • decreased T cell number (MP:0005018)

  • decreased body size (MP:0001265)

  • decreased body weight (MP:0001262)

  • decreased circulating alanine transaminase level (MP:0002942)

  • decreased circulating follicle stimulating hormone level (MP:0002790)

  • decreased circulating interleukin-2 level (MP:0008600)

  • decreased circulating interleukin-6 level (MP:0008597)

  • decreased circulating luteinizing hormone level (MP:0002773)

  • decreased circulating tumor necrosis factor level (MP:0008554)

  • decreased dopamine level (MP:0005643)

  • decreased gamma-delta intraepithelial T cell number (MP:0008351)

  • decreased inflammatory response (MP:0001876)

  • decreased interferon-gamma secretion (MP:0008567)

  • decreased leukocyte cell number (MP:0000221)

  • decreased lymphocyte cell number (MP:0005016)

  • decreased metastatic potential (MP:0001273)

  • decreased skeletal muscle fiber size (MP:0009400)

  • decreased skeletal muscle mass (MP:0004819)

  • decreased susceptibility to bacterial infection (MP:0002411)

  • decreased susceptibility to parasitic infection (MP:0005026)

  • decreased susceptibility to viral infection (MP:0002410)

  • decreased thymocyte number (MP:0000715)

  • decreased tumor incidence (MP:0002052)

  • deformed nails (MP:0000580)

  • female infertility (MP:0001926)

  • hairless (MP:0003815)

  • hyperactivity (MP:0001399)

  • impaired spatial learning (MP:0012307)

  • impaired swimming (MP:0001522)

  • increased IgA level (MP:0002495)

  • increased bone mineral density (MP:0000062)

  • increased erythroid progenitor cell number (MP:0003135)

  • increased length of allograft survival (MP:0004751)

  • increased plasmacytoma incidence (MP:0010286)

  • increased stereotypic behavior (MP:0001409)

  • increased susceptibility to viral infection (MP:0002418)

  • increased susceptibility to viral infection induced morbidity/mortality (MP:0009791)

  • increased thymocyte apoptosis (MP:0009541)

  • infertility (MP:0001924)

  • nail dystrophy (MP:0012400)

  • no abnormal phenotype detected (MP:0002169)

  • postnatal growth retardation (MP:0001732)

  • postnatal lethality, incomplete penetrance (MP:0011086)

  • premature death (MP:0002083)

  • reduced hair shaft melanin granule number (MP:0008732)

  • reduced male fertility (MP:0001922)

  • short nails (MP:0012399)

  • short vibrissae (MP:0001282)

  • small ovary (MP:0001127)

  • small spleen (MP:0000692)

  • thin skin (MP:0001199)

  • thrombocytosis (MP:0005505)

  • wavy vibrissae (MP:0001279)
    • Detailed phenotype data

    Ordering Information

    供与核酸E. coli lacZ, mouse phosphoglycerate kinase promoter (PGK promoter), E. coli neo, mouse tenascin genomic DNA
    Research application
    提供条件研究成果の公表にあたって寄託者の指定する文献を引用する。Am. J. Pathol., 152, 1237-1245 (1998). J. Invest. Dermatol., 111, 930-935 (1998). Invest. Ophthalmol. Visual. Sci., 40, 1071-1080 (1999).
    DepositorRIKEN BRC（独立行政法人理化学研究所）
    Strain Status凍結胚のアイコン凍結胚
    Strain Availability凍結胚より作出したマウスを2~4ヶ月以内に提供可能
    凍結胚を1ヶ月以内に提供可能
    Additional Info.Necessary documents for ordering:
    1. Order form (Japanese / English)
    2. Category I MTA: MTA for distribution with RIKEN BRC (Japanese / English)
    3. Acceptance of responsibility for living modified organism (Japanese / English)

    Genotyping protocol -PCR-

    BRC mice in Publications

    No Data